Tufik Assad is a Respiratory physician. OpenAlex indexes 37 publications with 1,799 citations (h-index 17).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
725 Albany St
Shapiro 5, Suite B
Boston, MA 02118
Telephone
617-414-5951Registry record last updated 31 Dec 2015.
Industry payments
29 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year202514 payments
- Ethicon Inc.Program year20253 payments
- CSL BehringProgram year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
67.8%Corticosteroid42.1%Trelegy Ellipta54%Breztri Aerosphere12%Symbicort11%Breo Ellipta9%Budesonide-Formoterol Fumarate9%Breyna3%Arnuity Ellipta2%Part D<11 patientsbeta2-Adrenergic Agonist12.2%Albuterol Sulfate Hfa93%Ventolin Hfa7%Part D<11 patients+ 5 more classes in this area
Metabolism & gastrointestinal
11.9%Corticosteroid11.1%Prednisone100%Part D≥105 patientsProton pump inhibitor0.8%Pantoprazole Sodium100%Part D<11 patientsCancer & immunology
6.9%Kinase inhibitor6.2%Ofev100%Part D≥12 patientsPyridone0.7%Pirfenidone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study
The Lancet Respiratory Medicine
2020 - Hypochloremia Is a Noninvasive Predictor of Mortality in Pulmonary Arterial Hypertension
Journal of the American Heart Association
2020 - Mendelian randomisation analysis of red cell distribution width in pulmonary arterial hypertension
European Respiratory Journal
2019
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Fernando Martinez, MD
University of Massachusetts Chan Medical School
David Gozal, MD
Marshall University
Ronald Crystal, MD
Weill Cornell Medicine
Bartolome Celli, MD
Brigham and Women's Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”